Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 15 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - tablet - aripiprazole 30 mg - psycholeptics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - gefitinib - film-coated tablet - 250 milligram(s) - protein kinase inhibitors; gefitinib

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - daptomycin - powder for solution for injection/infusion - daptomycin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - daptomycin - powder for solution for injection/infusion - daptomycin

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - atosiban - concentrate for solution for infusion - 37.5 mg/5ml - other gynecologicals; atosiban

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 10 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 15 mg - psycholeptics

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - aripiprazole - orodispersible tablet - aripiprazole 30 mg - psycholeptics

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine accord is indicated for the treatment of patients with,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ,? chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), ,? acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), ,in whom allogenic stem cell transplantation is not indicated.